In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Exicure (XCUR), with a price target of $8.00. The company’s shares closed last Tuesday at $1.51.
According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 26.0% and a 66.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Springworks Therapeutics, and Protalix Biotherapeutics.
Currently, the analyst consensus on Exicure is a Moderate Buy with an average price target of $7.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.84 and a one-year low of $0.96. Currently, Exicure has an average volume of 258.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exicure, Inc. engages in the provision of clinical stage biotechnology company. It offers 3-dimensional, spherical nucleic acid architecture unlocks the potential of nucleic acid therapeutics. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.
